{"id":"omacetaxine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Synribo","Homoharringtonine","Phase 1","Phase 2","HHT"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T03:40:53.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic myeloid leukemia","diseaseId":"chronic-myeloid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04926285","phase":"PHASE1","title":"Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2022-06-21","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":6},{"nctId":"NCT03564873","phase":"PHASE1, PHASE2","title":"Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2018-09-17","conditions":"High Grade Myelodysplastic Syndromes","enrollment":28},{"nctId":"NCT04874194","phase":"PHASE1, PHASE2","title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT00462943","phase":"PHASE2","title":"Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-03-07","conditions":"Chronic Myeloid Leukemia","enrollment":100},{"nctId":"NCT00375219","phase":"PHASE2","title":"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2006-09-20","conditions":"Chronic Myeloid Leukemia","enrollment":103},{"nctId":"NCT02078960","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-10-09","conditions":"Chronic Myeloid Leukemia","enrollment":10},{"nctId":"NCT02440568","phase":"PHASE1, PHASE2","title":"AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2015-06-05","conditions":"Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT02159872","phase":"PHASE2","title":"Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-18","conditions":"Leukemia","enrollment":48},{"nctId":"NCT03135054","phase":"PHASE2","title":"Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-10-01","conditions":"AML, FLT3-ITD Mutation","enrollment":40},{"nctId":"NCT03170895","phase":"PHASE2","title":"Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2017-07-01","conditions":"AML, FLT3-ITD Mutation","enrollment":5},{"nctId":"NCT01873495","phase":"PHASE2","title":"Omacetaxine for Consolidation and Maintenance","status":"TERMINATED","sponsor":"Emory University","startDate":"2013-05","conditions":"Acute Myelogenous Leukemia (AML)","enrollment":7},{"nctId":"NCT01272245","phase":"PHASE2","title":"Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-07","conditions":"Leukemia","enrollment":36},{"nctId":"NCT02141477","phase":"PHASE1","title":"Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-06","conditions":"Leukemia","enrollment":2},{"nctId":"NCT02835794","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2016-08","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT02029417","phase":"PHASE2","title":"Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2014-07","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":2},{"nctId":"NCT01844869","phase":"PHASE1","title":"An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Hematologic Malignancies, Solid Tumors","enrollment":6},{"nctId":"NCT00114959","phase":"PHASE2","title":"Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)","status":"TERMINATED","sponsor":"ChemGenex Pharmaceuticals","startDate":"2005-10","conditions":"Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase","enrollment":15},{"nctId":"NCT00675350","phase":"PHASE1","title":"Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors","status":"COMPLETED","sponsor":"ChemGenex Pharmaceuticals","startDate":"2008-04","conditions":"Hematologic Tumors","enrollment":12},{"nctId":"NCT00003694","phase":"PHASE2","title":"Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-03","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia","enrollment":60},{"nctId":"NCT00002574","phase":"PHASE2","title":"Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1994-09","conditions":"Leukemia","enrollment":87},{"nctId":"NCT00006364","phase":"PHASE2","title":"Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-11","conditions":"Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia","enrollment":50},{"nctId":"NCT00003239","phase":"PHASE2","title":"Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1998-03","conditions":"Leukemia","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":133,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Omacetaxine","genericName":"Omacetaxine","companyName":"University of Illinois at Chicago","companyId":"university-of-illinois-at-chicago","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-10-26T00:00:00.000Z","mah":"TEVA PHARMS INTL","brand_name_local":"SYNRIBO","application_number":"NDA203585"}],"trialStats":{"total":5,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}